SCHEMBL755467

SCHEMBL755467

CC[C@@H](C)Oc1cccc(C(=O)OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
TP53 P04637 2/20 0.50
LOXL2 Q9Y4K0 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TSHR P16473 1/20 0.49
CYP4F2 P78329 1/20 0.49
CYP4A11 Q02928 1/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 1/20 0.48
BLM P54132 1/20 0.48
MTNR1A P48039 6/20 0.48
MTNR1B P49286 6/20 0.48
MRGPRX4 Q96LA9 1/20 0.47
MEN1 O00255 1/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4857337 1.00 SMN1; SMN2 (0.50) SMN1; SMN2TP53LOXL2ALDH1A1TSHR
SCHEMBL9700206 0.89 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1TSHRMTNR1AMTNR1B
SCHEMBL12124925 0.88 TAS1R3 (0.53) SMN1; SMN2TP53LOXL2ALDH1A1CYP4F2
SCHEMBL930888 0.86 CYP4F2 (0.50) SMN1; SMN2ALDH1A1TSHRCYP4F2CYP4A11
SCHEMBL1107687 0.86 SMN1; SMN2 (0.49) SMN1; SMN2TP53LOXL2ALDH1A1CYP4F2
SCHEMBL9700210 0.85 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1TSHRMTNR1AMTNR1B
SCHEMBL931250 0.84 KMT2A (0.59) SMN1; SMN2TP53ALDH1A1TSHRNPC1
SCHEMBL8651136 0.84 L3MBTL1 (0.48) SMN1; SMN2TP53LOXL2ALDH1A1CYP4F2
SCHEMBL6174966 0.83 SMN1; SMN2 (0.59) SMN1; SMN2TP53LOXL2ALDH1A1TSHR
SCHEMBL28281866 0.83 SMN1; SMN2 (0.49) SMN1; SMN2TP53LOXL2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211904-B2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-07-03 US disclosed
EP-1910364-B1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-03-21 EP disclosed
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease BACE1, APP, PSEN1 SMN1; SMN2 2111/4885TP53 3781/4885LOXL2 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.